Search

Your search keyword '"Dominici, Marcello"' showing total 169 results
Start Over Author "Dominici, Marcello"
169 results on '"Dominici, Marcello"'

1. PAD4-Induced NETosis Via Cathepsin G–Mediated Platelet-Neutrophil Interaction in ChAdOx1 Vaccine-Induced Thrombosis—Brief Report

Author

Carnevale, Roberto, Leopizzi, Martina, Dominici, Marcello, d’Amati, Giulia, Bartimoccia, Simona, Nocella, Cristina, Cammisotto, Vittoria, D’Amico, Alessandra, Castellani, Valentina, Baratta, Francesco, Bertelli, Alessia, Arrivi, Alessio, Toni, Danilo, De Michele, Manuela, Pignatelli, Pasquale, Marcucci, Rossella, and Violi, Francesco

Published
2023
Full Text
View/download PDF

2. Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis

Author

Valgimigli, Marco, Mehran, Roxana, Windecker, Stephan, Vranckx, Pascal, Serruys, Patrick, Steg, Gabriel P., Hamm, Christian, Baber, Usman, Angiolillo, Dominick J., Cohen, David J., Dangas, George D., Mehta, Shamir, Gibson, Michael C., Kastrati, Adnan, Krucoff, Mitchel, Ohman, Magnus E., Gurbel, Paul, Henry, Timothy D., Moliterno, David, Sharma, Samin K., Pocock, Stuart, Jüni, Peter, da Costa, Bruno R., Kirkham, Brian, Sartori, Samantha, Heg, Dierik, McFadden, Eugene, Leonardi, Sergio, Piccolo, Raffaele, Franzone, Anna, Marx, Steven O., Darrow, Bruce, Corvaja, Nicola, DeStefano, Douglas, Ghodsi, Newsha, Meller, Jose, Franklin-Bond, Theresa, Cha, Jin Young, Waseem, Zaha, Huber, Kurt, Weisz, Giora, Kornowski, Ran, Kunadian, Vijay, Oldroyd, Keith, Yaling, Han, Kaul, Upendra, Witzenbichler, Bernhard, Dzavik, Vladimir, Gil, Robert, Dudek, Dariuz, Sardella, Gennaro, Escaned, Javier, Shlofmitz, Richard, Briguori, Carlo, Benit, Edouard, Liebetrau, Christoph, Janssens, Luc, Ferrario, Maurizio, Zurakowski, Aleksander, Diletti, Roberto, Dominici, Marcello, Slagboom, Ton, Buszman, Paweł, Bolognese, Leonardo, Tumscitz, Carlo, Bryniarski, Krzysztof, Aminian, Adel, Vrolix, Mathias, Petrov, Ivo, Garg, Scot, Naber, Christoph, Prokopczuk, Janusz, Steg, Philippe Gabriel, McFadden, Eùgene P., Cao, Davide, Mehta, Shamir R., Serruys, Patrick W., Gibson, C. Michael, Oldroyd, Keith G., and Heg, Dik

Published
2021
Full Text
View/download PDF

3. Endothelial shear stress and vascular remodeling in bioresorbable scaffold and metallic stent

Author

Tenekecioglu, Erhan, Katagiri, Yuki, Takahashi, Kuniaki, Tomaniak, Mariusz, Dudek, Dariusz, Cequier, Angel, Carrié, Didier, Iñiguez, Andrés, Johannes van der Schaaf, Rinse, Dominici, Marcello, Boven, Ad J.van, Helqvist, Steffen, Sabaté, Manel, Baumbach, Andreas, Piek, Jan J., Wykrzykowska, Joanna J., Kitslaar, Pieter, Dijkstra, Jouke, Reiber, Johan H.C., Chevalier, Bernard, Ural, Dilek, Pekkan, Kerem, Bourantas, Christos V., Gijsen, Frank, Onuma, Yoshinobu, Torii, Ryo, and Serruys, Patrick W.

Published
2020
Full Text
View/download PDF

5. Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial

Author

Takahashi, Kuniaki, Kogame, Norihiro, Tomaniak, Mariusz, Chichareon, Ply, Chang, Chun-Chin, Modolo, Rodrigo, Benit, Edouard, Liebetrau, Christoph, Janssens, Luc, Ferrario, Maurizio, Zurakowski, Aleksander, van Geuns, Robert Jan, Dominici, Marcello, Huber, Kurt, Buszman, Pawel, Bolognese, Leonardo, Tumscitz, Carlo, Żmudka, Krzysztof, Aminian, Adel, Vrolix, Mathias, Petrov, Ivo, Wykrzykowska, Joanna J., de Winter, Robbert J., Hamm, Christian, Steg, Philippe Gabriel, Onuma, Yoshinobu, Valgimigli, Marco, Windecker, Stephan, Vranckx, Pascal, Garg, Scot, and Serruys, Patrick W.

Published
2020
Full Text
View/download PDF

6. Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting

Author

Franzone, Anna, McFadden, Eugène, Leonardi, Sergio, Piccolo, Raffaele, Vranckx, Pascal, Serruys, Patrick W., Benit, Edouard, Liebetrau, Christoph, Janssens, Luc, Ferrario, Maurizio, Zurakowski, Aleksander, Diletti, Roberto, Dominici, Marcello, Huber, Kurt, Slagboom, Ton, Buszman, Paweł, Bolognese, Leonardo, Tumscitz, Carlo, Bryniarski, Krzysztof, Aminian, Adel, Vrolix, Mathias, Petrov, Ivo, Garg, Scot, Naber, Christoph, Prokopczuk, Janusz, Hamm, Christian, Steg, Philippe Gabriel, Heg, Dik, Jüni, Peter, Windecker, Stephan, and Valgimigli, Marco

Published
2019
Full Text
View/download PDF

8. Repeated Glutathione Sodium Salt Infusion May Counteract Contrast-Associated Acute Kidney Injury Occurrence in ST-Elevation Myocardial Infarction Patients Undergoing Primary PCI: A Randomized Subgroup Analysis of the GSH 2014 Trial

Author

Arrivi, Alessio, primary, Pucci, Giacomo, additional, Sordi, Martina, additional, Dominici, Marcello, additional, Barillà, Francesco, additional, Carnevale, Roberto, additional, Morgantini, Amalia, additional, Rosati, Riccardo, additional, Mangieri, Enrico, additional, and Tanzilli, Gaetano, additional

Published
2023
Full Text
View/download PDF

9. Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention

Author

Ono, Masafumi, Onuma, Yoshinobu, Kawashima, Hideyuki, Hara, Hironori, Gao, Chao, Wang, Rutao, O'Leary, Neil, Benit, Edouard, Janssens, Luc, Ferrario, Maurizio, Żurakowski, Aleksander, Dominici, Marcello, Huber, Kurt, Buszman, Paweł, Garg, Scot, Wykrzykowska, Joanna J, Piek, Jan J, Jüni, Peter, Hamm, Christian, Windecker, Stephan, Vranckx, Pascal, Deliargyris, Efthymios N, Bhatt, Deepak L, Storey, Robert F, Valgimigli, Marco, Serruys, Patrick W, Graduate School, Cardiology, ACS - Atherosclerosis & ischemic syndromes, ACS - Heart failure & arrhythmias, Ono, Masafumi/0000-0002-3919-5648, Gao, Chao/0000-0002-0390-8060, and Storey, Robert/0000-0002-6677-6229

Subjects
Ticagrelor, FOCUSED UPDATE, proton pump inhibitor, Myocardial Infarction, 610 Medicine & health, THERAPY, DEFINITIONS, Humans, Radiology, Nuclear Medicine and imaging, ticagrelor monotherapy, RISK, OUTCOMES, drug interaction, Aspirin, OMEPRAZOLE, percutaneous coronary intervention, Proton Pump Inhibitors, General Medicine, dual antiplatelet therapy, Treatment Outcome, CLOPIDOGREL, PLATELET INHIBITION, Cardiology and Cardiovascular Medicine, 610 Medizin und Gesundheit, Platelet Aggregation Inhibitors, CLINICAL-TRIALS
Abstract

Background Several studies have suggested that proton pump inhibitors (PPIs) may reduce the antiplatelet effects of clopidogrel and/or aspirin, possibly leading to cardiovascular events. Aims We aimed to investigate the association between PPI and clinical outcomes in patients treated with ticagrelor monotherapy or conventional antiplatelet therapy after percutaneous coronary intervention (PCI). Methods This is a subanalysis of the randomized GLOBAL LEADERS trial, comparing the experimental antiplatelet arm (23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy [DAPT]) with the reference arm (12-month aspirin monotherapy following 12-month DAPT) after PCI. Patient-oriented composite endpoints (POCEs: all-cause mortality, myocardial infarction, stroke, or repeat revascularization) and its components were assessed stratified by PPI use as a time-dependent covariate in patients with the experiment or reference antiplatelet arm. Results Among 15,839 patients, 2115 patients (13.5%) experienced POCE at 2 years. In the reference arm, the use of PPIs was independently associated with POCE (hazard ratio [HR]: 1.27; 95% confidence interval [CI]: 1.12-1.44) and its individual components, whereas it was not in the experimental arm (HR: 1.04; 95% CI: 0.92-1.19; p(interaction) = 0.035). During the second-year follow-up, patients taking aspirin with PPIs had a significantly higher risk of POCE compared to those on aspirin without PPIs (HR: 1.57; 95% CI: 1.27-1.94), whereas the risk did not differ significantly irrespective of PPI in ticagrelor monotherapy group (HR: 1.03; 95% CI: 0.83-1.28; p(interaction) = 0.008). Conclusions In contrast to conventional antiplatelet strategy, there were no evidence suggesting the interaction between ticagrelor monotherapy and PPIs on increased cardiovascular events, which should be confirmed in further studies. Clinical Trial Registration URL: The GLOBAL LEADERS trial was supported by unrestricted grants from AstraZeneca, Biosensors, and The Medicines Company. ECRI (European Cardiovascular Research Institute) was formally the sponsor of the study. GLOBAL LEADERS was sponsored by the European Clinical Research Institute, which received funding from Biosensors International, AstraZeneca, and the Medicines Company. P. J. is a Tier 1 Canada Research Chair in Clinical Epidemiology of Chronic Diseases. This study was completed, in part, with funding from the Canada Research Chairs Program. Open access funding provided by IReL.

Published
2022

10. The Combined Treatment of Glutathione Sodium Salt and Ascorbic Acid for Preventing Contrast-Associated Acute Kidney Injury in ST-Elevation Myocardial Infarction Patients Undergoing Primary PCI: A Hypothesis to Be Validated

Author

Arrivi, Alessio, primary, Truscelli, Giovanni, additional, Pucci, Giacomo, additional, Barillà, Francesco, additional, Carnevale, Roberto, additional, Nocella, Cristina, additional, Sordi, Martina, additional, Dominici, Marcello, additional, Tanzilli, Gaetano, additional, and Mangieri, Enrico, additional

Published
2023
Full Text
View/download PDF

11. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial

Author

Serruys, Patrick W, Chevalier, Bernard, Sotomi, Yohei, Cequier, Angel, Carrié, Didier, Piek, Jan J, Van Boven, Ad J, Dominici, Marcello, Dudek, Dariusz, McClean, Dougal, Helqvist, Steffen, Haude, Michael, Reith, Sebastian, de Sousa Almeida, Manuel, Campo, Gianluca, Iñiguez, Andrés, Sabaté, Manel, Windecker, Stephan, and Onuma, Yoshinobu

Published
2016
Full Text
View/download PDF

13. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial

Author

Serruys, Patrick W, Chevalier, Bernard, Dudek, Dariusz, Cequier, Angel, Carrié, Didier, Iniguez, Andres, Dominici, Marcello, van der Schaaf, René J, Haude, Michael, Wasungu, Luc, Veldhof, Susan, Peng, Lei, Staehr, Peter, Grundeken, Maik J, Ishibashi, Yuki, Garcia-Garcia, Hector M, and Onuma, Yoshinobu

Published
2015
Full Text
View/download PDF

14. Early and prolonged glutathione infusion favourably impacts length of hospital stay in ST-elevation myocardial infarction patients: a sub-analysis of the GSH2014 trial

Author

Arrivi, Alessio, Pucci, Giacomo, Placanica, Attilio, Bier, Nicola, Sordi, Martina, Dominici, Marcello, Carnevale, Roberto, Tanzilli, Gaetano, and Mangieri, Enrico

Subjects
ST elevation myocardial infarction, Angioplasty, Length of stay, Cardiology and Cardiovascular Medicine, Glutathione
Abstract

Developing strategies aimed to shorten the length of stay (LOS) in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) is a healthcare goal to be pursued. We carried out a sub-analysis of the GSH 2014 trial to assess the potentiality of glutathione sodium salt infusion to impact on LOS.100 consecutive patients with STEMI, aged more than 18 years and referred to the three enrolling centers for primary angioplasty (p-PCI), were asked to participate to the GSH 2014 trial. Fifty patients were randomized to treatment group and fifty to placebo; treatment consisted into an intravenous infusion of gluthatione sodium salt over 10 min before p-PCI; after interventions, glutathione was infused at the same doses at 24, 48 and 72 h elapsing time. A stepwise linear multivariate model was built in order to assess independent predictors of LOS.Subjects receiving infusion of glutathione sodium salt had a significantly lower LOS than subjects receiving placebo (8.6±3 vs 10.8±4 days, p=0.006). At multivariate analysis, the randomization to GSH group was negatively associated with length of stay (β±SEβ -1.64±0.74, cumulative R2 0.43, p=0.03) independently from age, sex, cardiovascular risk factors, number of treated vessels, infarct-related coronary artery (left anterior descending artery as reference) and enrolment hospital.Results from this sub-analysis support the hypothesis that an early and prolonged glutathione sodium salt administration, as antioxidant therapy to patients with STEMI, may favorably impact on LOS. Further studies with larger sample size are necessary to confirm these data.

Published
2022

15. The impact of UEFA Euro 2020 football championship on Takotsubo Syndrome: Results of a multicenter national registry

Author

Polimeni, Alberto, primary, Spaccarotella, Carmen, additional, Ielapi, Jessica, additional, Esposito, Giovanni, additional, Ravera, Amelia, additional, Martuscelli, Eugenio, additional, Ciconte, Vincenzo, additional, Menichelli, Maurizio, additional, Varbella, Ferdinando, additional, Imazio, Massimo, additional, Navazio, Alessandro, additional, Sinagra, Gianfranco, additional, Oberhollenzer, Rainer, additional, Sibilio, Gerolamo, additional, Cacciavillani, Luisa, additional, Meloni, Luigi, additional, Dominici, Marcello, additional, Tomai, Fabrizio, additional, Amico, Francesco, additional, Corda, Marco, additional, Musumeci, Giuseppe, additional, Lupi, Alessandro, additional, Zezza, Luigi, additional, De Caterina, Raffaele, additional, Cernetti, Carlo, additional, Metra, Marco, additional, Rossi, Lidia, additional, Calabrò, Paolo, additional, Murrone, Adriano, additional, Volpe, Massimo, additional, Caldarola, Pasquale, additional, Carugo, Stefano, additional, Cortese, Bernardo, additional, Valenti, Renato, additional, Boriani, Giuseppe, additional, Fedele, Francesco, additional, Ventura, Giorgio, additional, Manes, Maria Teresa, additional, Colavita, Angela Rita, additional, Feola, Mauro, additional, Versaci, Francesco, additional, Assennato, Pasquale, additional, Arena, Giuseppe, additional, Ceravolo, Roberto, additional, Amodeo, Vincenzo, additional, Tortorici, Gianfranco, additional, Nassiacos, Daniele, additional, Antonicelli, Roberto, additional, Esposito, Nicolino, additional, Favale, Stefano, additional, Licciardello, Giovanni, additional, Tedesco, Luigi, additional, and Indolfi, Ciro, additional

Published
2022
Full Text
View/download PDF

16. A Case Report of an Unusual Acute Intramural Hematoma Disguise as Pulmonary Embolism.

Author

Dell'Uomo, Marco, Conti, Serenella, Di Meo, Federica, Dominici, Marcello, and Borghetti, Valentino

Abstract

Aortic intramural hematoma (IMH) is characterized by an aortic wall hematoma without intimal flap and it is a variant of acute aortic syndromes (AAS). This entity may represent 10%-25% of the AAS involving the ascending aorta and aortic arch (Stanford Type A) in 10%-30% of cases and the descending thoracic aorta (Stanford Type B) in 60%-70% of cases. IMH impairs the aortic wall and may progress to either inward disruption of the intima, which finally induces typical dissection or outward rupture of the aorta. The literature describes some clinical reports where Type A aortic dissection mimics a pulmonary embolism but is not described as a case provoked by IMH with outward rupture of the aorta. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Comparison of everolimus-eluting bioresorbable scaffolds with everolimus-eluting metallic stents for treatment of coronary artery stenosis: Three-year follow-up of the ABSORB II randomized trial

Author

Collet, Carlos, primary, Sotomi, Yohei, additional, Chevalier, Bernard, additional, Fillat, Angel Ramón Cequier, additional, Carrié, Didier, additional, Piek, Jan, additional, van Boven, A.J., additional, Dominici, Marcello, additional, Dudek, Dariusz, additional, McClean, Dougal, additional, Helqvist, Steffen, additional, Haude, Michael, additional, Reith, Sebastian, additional, Almeida, Manuel de Sousa, additional, Campo, Gianluca, additional, Iñiguez, Andrés, additional, van Geuns, Robert-Jan M., additional, Smits, Pieter, additional, Sabaté, Manel, additional, Windecker, Stephan, additional, Onuma, Yoshinobu, additional, and Serruys, Patrick W.J.C., additional

Published
2017
Full Text
View/download PDF

19. PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens:Insights from the GLOBAL LEADERS and GLASSY

Author

Gragnano, Felice, Heg, Dik, Franzone, Anna, McFadden, Eugène P., Leonardi, Sergio, Piccolo, Raffaele, Vranckx, Pascal, Branca, Mattia, Serruys, Patrick W., Benit, Edouard, Liebetrau, Christoph, Janssens, Luc, Ferrario, Maurizio, Zurakowski, Aleksander, Diletti, Roberto, Dominici, Marcello, Huber, Kurt, Slagboom, Ton, Buszman, Paweł, Bolognese, Leonardo, Tumscitz, Carlo, Bryniarski, Krzysztof, Aminian, Adel, Vrolix, Mathias, Petrov, Ivo, Garg, Scot, Naber, Christoph, Prokopczuk, Janusz, Hamm, Christian, Steg, Philippe Gabriel, Jüni, Peter, Windecker, Stephan, Valgimigli, Marco, Gragnano, Felice, Heg, Dik, Franzone, Anna, McFadden, Eugène P., Leonardi, Sergio, Piccolo, Raffaele, Vranckx, Pascal, Branca, Mattia, Serruys, Patrick W., Benit, Edouard, Liebetrau, Christoph, Janssens, Luc, Ferrario, Maurizio, Zurakowski, Aleksander, Diletti, Roberto, Dominici, Marcello, Huber, Kurt, Slagboom, Ton, Buszman, Paweł, Bolognese, Leonardo, Tumscitz, Carlo, Bryniarski, Krzysztof, Aminian, Adel, Vrolix, Mathias, Petrov, Ivo, Garg, Scot, Naber, Christoph, Prokopczuk, Janusz, Hamm, Christian, Steg, Philippe Gabriel, Jüni, Peter, Windecker, Stephan, and Valgimigli, Marco

Abstract

Aims The five-item PRECISE-DAPT, integrating age, haemoglobin, white-blood-cell count, creatinine clearance, and prior bleeding, predicts bleeding risk in patients on dual antiplatelet therapy (DAPT) after stent implantation. We sought to assess whether the bleeding risk prediction offered by the PRECISE-DAPT remains valid among patients receiving ticagrelor monotherapy from 1 month onwards after coronary stenting instead of standard DAPT and having or not having centrally adjudicated bleeding endpoints. Methods The PRECISE-DAPT was calculated in 14 928 and 7134 patients from GLOBAL LEADERS and GLASSY trials, re- and results spectively. The ability of the score to predict Bleeding Academic Research Consortium 3 or 5 bleeding was assessed and compared among patients on ticagrelor monotherapy (experimental strategy) or standard DAPT (reference strategy) from 1 month after drug-eluting stent implantation. Bleeding endpoints were investigator-reported or centrally adjudicated in GLOBAL LEADERS and GLASSY, respectively. At 2 years, the c-indexes for the score among patients treated with the experimental or reference strategy were 0.67 [95% confidence interval (CI): 0.63-0.71] vs. 0.63 (95% CI: 0.59-0.67) in GLOBAL LEADERS (P = 0.27), and 0.67 (95% CI: 0.61-0.73) vs. 0.66 (95% CI: 0.61-0.72) in GLASSY (P = 0.88). Decision curve analysis showed net benefit using the PRECISE-DAPT to guide bleeding risk assessment under both treatment strategies. Results were consistent between investigator-reported and adjudicated endpoints and using the simplified four-item PRECISE-DAPT. Conclusion The PRECISE-DAPT offers a prediction model that proved similarly effective to predict clinically relevant bleeding among patients on ticagrelor monotherapy from 1 month after coronary stenting compared with standard DAPT and appears to be unaffected by the presence or absence of adjudicated bleeding endpoints.

Published
2022

21. Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug‐Eluting Stent Implantation: Per‐Protocol Analysis of the GLOBAL LEADERS Trial

Author

Gragnano, Felice, primary, Zwahlen, Marcel, additional, Vranckx, Pascal, additional, Heg, Dik, additional, Schmidlin, Kurt, additional, Hamm, Christian, additional, Steg, Philippe Gabriel, additional, Gargiulo, Giuseppe, additional, McFadden, Eugene P., additional, Onuma, Yoshinobu, additional, Chichareon, Ply, additional, Benit, Edouard, additional, Möllmann, Helge, additional, Janssens, Luc, additional, Leonardi, Sergio, additional, Zurakowski, Aleksander, additional, Arrivi, Alessio, additional, Van Geuns, Robert Jan, additional, Huber, Kurt, additional, Slagboom, Ton, additional, Calabrò, Paolo, additional, Serruys, Patrick W., additional, Jüni, Peter, additional, Valgimigli, Marco, additional, Windecker, Stephan, additional, Abdellaoui, Mohamed, additional, Adlam, David, additional, Akin, Ibrahim, additional, Gonzalez‐Trevilla, Agustin Albarran, additional, Almeida, Manuel, additional, Neto, Pedro Alves Lemos, additional, Aminian, Adel, additional, Anderson, Richard, additional, Andreae, Rick, additional, Angioi, Michael, additional, Asano, Taku, additional, Barbato, Emanuele, additional, Barlis, Peter, additional, Barraud, Pascal, additional, Bertrand, Olivier, additional, Beygui, Farzin, additional, Bolognese, Leonardo, additional, Botelho, Roberto, additional, Bouwman, Coby, additional, Bressers, Marco, additional, Brunel, Philippe, additional, Buszman, Pawel, additional, Buysschaert, Ian, additional, da Silva, Pedro Canas, additional, Carrie, Didier, additional, Cequier, Angel, additional, Chang, Chun Chin, additional, Chowdhary, Saqib, additional, Collet, Carlos, additional, Colombo, Antonio, additional, Cotton, James, additional, Ferreira, Rui Cruz, additional, Curello, Salvatore, additional, Curzen, Nick, additional, de Bot, Judith, additional, de Vreede, Tone, additional, Karth, Georg Delle, additional, Dijksma, Lynn, additional, Dominici, Marcello, additional, Édes, István, additional, Eeckhout, Eric, additional, Eitel, Ingo, additional, Faluközy, József, additional, Fath‐Ordoubadi, Farzin, additional, Ferrario, Maurizio, additional, Fontos, Geza, additional, Diaz, Jose Francisco, additional, Quintella, Edgard Freitas, additional, Frey, Bernhard, additional, Friedrich, Guy, additional, Galasko, Gavin, additional, Galuszka, Grzegorz, additional, Ribeiro, Vasco Gama, additional, Garg, Scot, additional, Geisler, Tobias, additional, Gelev, Valeri, additional, Ghandilyan, Art, additional, Goicolea, Javier, additional, Gori, Tommaso, additional, Gragnano, Felice, additional, Guimarães, Ana, additional, Haude, Michael, additional, Heijke, Pieter, additional, Antolin, Rosa Ana Hernández, additional, Hildick‐Smith, David, additional, Hillen, Dorien, additional, Hoekman, Ina, additional, Hofma, Sjoerd, additional, Holmvang, Lene, additional, Hoole, Stephen, additional, Horváth, Iván, additional, Hugense, Annemarie, additional, Ibrahim, Karim, additional, Iñiguez, Andres, additional, Isaaz, Karl, additional, Jambrik, Zoltán, additional, Jasionowicz, Pawel, additional, Jonk, Judith, additional, Jung, Werner, additional, Katagiri, Yuki, additional, Kogame, Norihiro, additional, Koh, Tian Hai, additional, Koning, René, additional, Konteva, Mariana, additional, Kőszegi, Zsolt, additional, Krackhardt, Florian, additional, Kreuger, Yvonne, additional, Kukreja, Neville, additional, Ladan, Boudijn, additional, Lantelme, Pierre, additional, Leandro, Sergio, additional, Leibundgut, Gregor, additional, Liebetrau, Christoph, additional, Lindeboom, Wietze, additional, Miguel, Carlos Macaya, additional, Mach, François, additional, Magro, Michael, additional, Maillard, Luc, additional, Manavifar, Negar, additional, Mauri, Laura, additional, McFadden, Eugene, additional, Merkely, Bela, additional, Miyazaki, Yosuke, additional, Młodziankowski, Adam, additional, Moccetti, Tiziano, additional, Modolo, Rodrigo, additional, Möllman, Helge, additional, Morelle, Jean‐François, additional, Moschovitis, Aris, additional, Ottesen, Michael Munndt, additional, Muurling, Martin, additional, Naber, Christoph Kurt, additional, Neumann, Franz‐Josef, additional, Oldroyd, Keith, additional, Ong, Paul, additional, Palsrok, Sanne, additional, Petrov, Ivo, additional, Plante, Sylvain, additional, Prokopczuk, Janusz, additional, Rademaker‐Havinga, Tessa, additional, Raffel, Christopher, additional, Rensing, Benno, additional, Roffi, Marco, additional, Royaards, Kees‐Jan, additional, Sabate, Manel, additional, Schächinger, Volker, additional, Seidler, Tim, additional, Peñaranda, Antonio Serra, additional, Serruys, Patrick, additional, Sikarulidze, Lali, additional, Soliman, Osama I, additional, Sousa, Amanda, additional, Spitzer, Ernest, additional, Stables, Rod, additional, Steg, Gabriel, additional, Steinwender, Clemens, additional, Subkovas, Eduardas, additional, Suryapranata, Harry, additional, Takahashi, Kuniaki, additional, Talwar, Suneel, additional, Teiger, Emmanuel, additional, Weele, Addy Ter, additional, Teurlings, Eva, additional, Thury, Attila, additional, Tijssen, Jan, additional, Tonev, Gincho, additional, Trendafilova‐Lazarova, Diana, additional, Tumscitz, Carlo, additional, Umans, Victor, additional, Ungi, Imre, additional, Valkov, Veselin, additional, van der Harst, Pim, additional, van Geuns, Robert Jan, additional, van Meijeren, Cokky, additional, Vassilev, Dobrin, additional, Velchev, Vasil, additional, Velthuizen, Esther, additional, Verheugt, Freek, additional, Vlcek, Natalia, additional, Dahl, Jürgen Vom, additional, Vrolix, Mathias, additional, Walsh, Simon, additional, Werner, Nikos, additional, Witsenburg, Maarten, additional, Zaman, Azfar, additional, Żmudka, Krzysztof, additional, Zrenner, Bernhard, additional, and Zweiker, Robert, additional

Published
2022
Full Text
View/download PDF

24. Glutathione Infusion Before and 3 Days After Primary Angioplasty Blunts Ongoing NOX2‐Mediated Inflammatory Response

Author

Tanzilli, Gaetano, primary, Arrivi, Alessio, additional, Placanica, Attilio, additional, Viceconte, Nicola, additional, Cammisotto, Vittoria, additional, Nocella, Cristina, additional, Barillà, Francesco, additional, Torromeo, Concetta, additional, Pucci, Giacomo, additional, Acconcia, Maria Cristina, additional, Granatelli, Antonino, additional, Basili, Stefania, additional, Dominici, Marcello, additional, Gaudio, Carlo, additional, Carnevale, Roberto, additional, and Mangieri, Enrico, additional

Published
2021
Full Text
View/download PDF

26. Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSY

Author

Leonardi, Sergio, Branca, Mattia, Franzone, Anna, McFadden, Eugene, Piccolo, Raffaele, Jüni, Peter, Vranckx, Pascal, Steg, Philippe Gabriel, Serruys, Patrick W., Benit, Edouard, Liebetrau, Christoph, Janssens, Luc, Ferrario, Maurizio, Zurakowski, Aleksander, Diletti, Roberto, Dominici, Marcello, Huber, Kurt, Slagboom, Ton, Buszman, Pawel, Bolognese, Leonardo, Tumscitz, Carlo, Bryniarski, Krzysztof, Aminian, Adel, Vrolix, Mathias, Petrov, Ivo, Garg, Scot, Naber, Cristoph, Prokopczuk, Janusz, Hamm, Christian, Heg, Dik, Windecker, Stephan, Valgimigli, Marco, Leonardi, Sergio, Branca, Mattia, Franzone, Anna, McFadden, Eugene, Piccolo, Raffaele, Jüni, Peter, Vranckx, Pascal, Steg, Philippe Gabriel, Serruys, Patrick W., Benit, Edouard, Liebetrau, Christoph, Janssens, Luc, Ferrario, Maurizio, Zurakowski, Aleksander, Diletti, Roberto, Dominici, Marcello, Huber, Kurt, Slagboom, Ton, Buszman, Pawel, Bolognese, Leonardo, Tumscitz, Carlo, Bryniarski, Krzysztof, Aminian, Adel, Vrolix, Mathias, Petrov, Ivo, Garg, Scot, Naber, Cristoph, Prokopczuk, Janusz, Hamm, Christian, Heg, Dik, Windecker, Stephan, and Valgimigli, Marco

Abstract

Background: Event adjudication by a clinical event committee (CEC) provides a standardized, independent outcome assessment. However, the added value of CEC to investigators reporting remains debated. GLASSY (GLOBAL LEADERS Adjudication Sub-Study) implemented, in a subset of the open-label, investigator-reported (IR) GLOBAL LEADERS trial, an independent adjudication process of reported and unreported potential outcome events (triggers). We describe metrics of GLASSY feasibility and efficiency, diagnostic accuracy of IR events, and their concordance with corresponding CEC-adjudicated events. Methods: We report the proportion of myocardial infarction, bleeding, stroke, and stent thrombosis triggers with sufficient evidence for assessment (feasibility) that were adjudicated as outcome events (efficiency), stratified by source (IR or non-IR). Using CEC-adjudicated events as criterion standard, we describe sensitivity, specificity, positive and negative predictive value, and global diagnostic accuracy of IR events. Using Gwet AC coefficient, we examine the concordance between IR- and corresponding CEC-adjudicated triggers. There was sufficient evidence for assessment for 2592 (98.3%) of 2636 triggers. Results: Overall, the adjudicated end point-to-trigger ratio was high and similar between IR- (88%) and non-IR-reported (87%) triggers. The global diagnostic accuracy and concordance between IR-reported and CEC-adjudicated outcome events was 0.70 (95% CI, 0.65-0.74) and 0.54 (95% CI, 0.45-0.62), respectively, for myocardial infarction; 0.77 (95% CI, 0.75-0.79) and 0.71 (95% CI, 0.68-0.74) for bleeding; 0.70 (95% CI, 0.62-0.79) and 0.59 (95% CI, 0.43-0.74) for stroke; 0.59 (95% CI, 0.52-0.66) and 0.39 (95% CI, 0.25-0.53) for stent thrombosis. For IR bleedings, the concordance with the CEC on type of events was generally weak. Conclusions: Implementing CEC adjudication in a pragmatic open-label trial with IR events is feasible and efficient. Our findings of modest global di

Published
2021

27. Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD in Elderly Patients Aged Above 75 Years: a Prespecified Analysis of the Randomized GLOBAL LEADERS Trial

Author

Tomaniak, Mariusz, Chichareon, Ply, Modolo, Rodrigo, Takahashi, Kuniaki, Chang, Chun Chin, Kogame, Norihiro, Spitzer, Ernest, Buszman, Pawel E, Van Geuns, Robert-Jan M, Valkov, Veselin, Steinwender, Clemens, Geisler, Tobias, Prokopczuk, Janusz, Sabaté, Manel, Zmudka, Krzysztof, Rademaker-Havinga, Tessa, Tijssen, Jan G P, Jüni, Peter, Hamm, Christian, Steg, Philippe Gabriel, Onuma, Yoshinobu, Vranckx, Pascal, Valgimigli, Marco, Windecker, Stephan, Baber, Usman, Anderson, Richard, Dominici, Marcello, and Serruys, Patrick W

Subjects
610 Medicine & health
Abstract

AIMS Antiplatelet treatment in the elderly post percutaneous coronary interventions (PCI) remains a complex issue. METHODS AND RESULTS A pre-specified analysis of randomized GLOBAL LEADERS (n=15991), comparing 23-month ticagrelor monotherapy (after one month of DAPT) with the reference treatment (12-month DAPT followed by 12 months of aspirin). Among elderly patients (>75 years; n=2565), the primary endpoint (two-year all-cause mortality or new Q-wave corelab-adjudicated myocardial infarction [MI]) occurred in 7.2% and 9.4% of patients in the ticagrelor monotherapy and the reference group, respectively, (hazard ratio [HR]0.75, 95% confidence interval [CI] 0.58-0.99,p=0.041;pint=0.23); BARC-defined bleeding type 3/5 occurred in 5.2% and 4.1%, respectively (HR1.29; 95%CI0.89-1.86;p=0.180;pint=0.06). The elderly with stable CAD had a higher rate of BARC 3/5 type bleeding (HR2.05, 95%CI1.18-3.55) with ticagrelor monotherapy versus the reference treatment (pint=0.02). Elderly patients had a lower rate of definite or probable stent thrombosis (ST) with ticagrelor monotherapy (0.4%vs.1.4%,p=0.015,pint=0.01),compared with the reference group. CONCLUSIONS In this prespecified, exploratory analysis of the overall neutral trial, there was no differential treatment effect of ticagrelor monotherapy (after one-month dual therapy with aspirin) found in elderly patients undergoing PCI with respect to the rate of the primary endpoint of all-cause death or new Q-wave MI. The lower rate of ST in the elderly with ticagrelor monotherapy is hypothesis-generating.

Published
2020
Full Text
View/download PDF

28. Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial

Author

Tomaniak, Mariusz, Chichareon, Ply, Modolo, Rodrigo, Takahashi, Kuniaki, Chang, Chun Chin, Kogame, Norihiro, Spitzer, Ernest, Buszman, Pawel E, van Geuns, Robert-Jan M, Valkov, Veselin, Steinwender, Clemens, Geisler, Tobias, Prokopczuk, Janusz, Sabaté, Manel, Zmudka, Krzysztof, Rademaker-Havinga, Tessa, Tijssen, Jan G P, Jüni, Peter, Hamm, Christian, Steg, Philippe Gabriel, Onuma, Yoshinobu, Vranckx, Pascal, Valgimigli, Marco, Windecker, Stephan, Baber, Usman, Anderson, Richard, Dominici, Marcello, Serruys, Patrick W, Tomaniak, Mariusz, Chichareon, Ply, Modolo, Rodrigo, Takahashi, Kuniaki, Chang, Chun Chin, Kogame, Norihiro, Spitzer, Ernest, Buszman, Pawel E, van Geuns, Robert-Jan M, Valkov, Veselin, Steinwender, Clemens, Geisler, Tobias, Prokopczuk, Janusz, Sabaté, Manel, Zmudka, Krzysztof, Rademaker-Havinga, Tessa, Tijssen, Jan G P, Jüni, Peter, Hamm, Christian, Steg, Philippe Gabriel, Onuma, Yoshinobu, Vranckx, Pascal, Valgimigli, Marco, Windecker, Stephan, Baber, Usman, Anderson, Richard, Dominici, Marcello, and Serruys, Patrick W

Abstract

AIMS Antiplatelet treatment in the elderly post percutaneous coronary interventions (PCI) remains a complex issue. Here we report the results of the pre-specified subgroup analysis of the GLOBAL LEADERS trial evaluating the long-term safety and cardiovascular efficacy of ticagrelor monotherapy among patients categorised according to the pre-specified cut-off value of 75 years of age. METHODS AND RESULTS This was a pre-specified analysis of the randomised GLOBAL LEADERS trial (n=15,991), comparing 23-month ticagrelor monotherapy (after one month of DAPT) with the reference treatment (12-month DAPT followed by 12 months of aspirin). Among elderly patients (>75 years; n=2,565), the primary endpoint (two-year all-cause mortality or new Q-wave core lab-adjudicated myocardial infarction [MI]) occurred in 7.2% and 9.4% of patients in the ticagrelor monotherapy and the reference group, respectively (hazard ratio [HR] 0.75, 95% confidence interval [CI]: 0.58-0.99, p=0.041; pint=0.23); BARC-defined bleeding type 3/5 occurred in 5.2% and 4.1%, respectively (HR 1.29, 95% CI: 0.89-1.86; p=0.180; pint=0.06). The elderly with stable CAD had a higher rate of BARC 3/5 type bleeding (HR 2.05, 95% CI: 1.18-3.55) with ticagrelor monotherapy versus the reference treatment (pint=0.02). Elderly patients had a lower rate of definite or probable stent thrombosis (ST) with ticagrelor monotherapy (0.4% vs 1.4%, p=0.015, pint=0.01), compared with the reference group. CONCLUSIONS In this pre-specified, exploratory analysis of the overall neutral trial, there was no differential treatment effect of ticagrelor monotherapy (after one-month dual therapy with aspirin) found in elderly patients undergoing PCI with respect to the rate of the primary endpoint of all-cause death or new Q-wave MI. The lower rate of ST in the elderly with ticagrelor monotherapy is hypothesis-generating. ClinicalTrials.gov identifier: NCT01813435.

Published
2020

29. Comparison of Investigator-Reported and Clinical Event Committee–Adjudicated Outcome Events in GLASSY

Author

Leonardi, Sergio, primary, Branca, Mattia, additional, Franzone, Anna, additional, McFadden, Eugene, additional, Piccolo, Raffaele, additional, Jüni, Peter, additional, Vranckx, Pascal, additional, Steg, Philippe Gabriel, additional, Serruys, Patrick W., additional, Benit, Edouard, additional, Liebetrau, Christoph, additional, Janssens, Luc, additional, Ferrario, Maurizio, additional, Zurakowski, Aleksander, additional, Diletti, Roberto, additional, Dominici, Marcello, additional, Huber, Kurt, additional, Slagboom, Ton, additional, Buszman, Pawel, additional, Bolognese, Leonardo, additional, Tumscitz, Carlo, additional, Bryniarski, Krzysztof, additional, Aminian, Adel, additional, Vrolix, Mathias, additional, Petrov, Ivo, additional, Garg, Scot, additional, Naber, Cristoph, additional, Prokopczuk, Janusz, additional, Hamm, Christian, additional, Heg, Dik, additional, Windecker, Stephan, additional, and Valgimigli, Marco, additional

Published
2021
Full Text
View/download PDF

32. PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY

Author

Gragnano, Felice, primary, Heg, Dik, additional, Franzone, Anna, additional, McFadden, Eugène P, additional, Leonardi, Sergio, additional, Piccolo, Raffaele, additional, Vranckx, Pascal, additional, Branca, Mattia, additional, Serruys, Patrick W, additional, Benit, Edouard, additional, Liebetrau, Christoph, additional, Janssens, Luc, additional, Ferrario, Maurizio, additional, Zurakowski, Aleksander, additional, Diletti, Roberto, additional, Dominici, Marcello, additional, Huber, Kurt, additional, Slagboom, Ton, additional, Buszman, Paweł, additional, Bolognese, Leonardo, additional, Tumscitz, Carlo, additional, Bryniarski, Krzysztof, additional, Aminian, Adel, additional, Vrolix, Mathias, additional, Petrov, Ivo, additional, Garg, Scot, additional, Naber, Christoph, additional, Prokopczuk, Janusz, additional, Hamm, Christian, additional, Steg, Philippe Gabriel, additional, Jüni, Peter, additional, Windecker, Stephan, additional, and Valgimigli, Marco, additional

Published
2020
Full Text
View/download PDF

33. Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial

Author

Tomaniak, Mariusz, primary, Chichareon, Ply, additional, Modolo, Rodrigo, additional, Takahashi, Kuniaki, additional, Chang, Chun Chin, additional, Kogame, Norihiro, additional, Spitzer, Ernest, additional, Buszman, Pawel E., additional, van Geuns, Robert-Jan M., additional, Valkov, Veselin, additional, Steinwender, Clemens, additional, Geisler, Tobias, additional, Prokopczuk, Janusz, additional, Sabaté, Manel, additional, Zmudka, Krzysztof, additional, Rademaker-Havinga, Tessa, additional, Tijssen, Jan G.P., additional, Jüni, Peter, additional, Hamm, Christian, additional, Steg, Philippe Gabriel, additional, Onuma, Yoshinobu, additional, Vranckx, Pascal, additional, Valgimigli, Marco, additional, Windecker, Stephan, additional, Baber, Usman, additional, Anderson, Richard, additional, Dominici, Marcello, additional, and Serruys, Patrick W., additional

Published
2020
Full Text
View/download PDF

34. Low-grade endotoxaemia enhances artery thrombus growth via Toll-like receptor 4: implication for myocardial infarction

Author

Carnevale, Roberto, primary, Sciarretta, Sebastiano, additional, Valenti, Valentina, additional, di Nonno, Flavio, additional, Calvieri, Camilla, additional, Nocella, Cristina, additional, Frati, Giacomo, additional, Forte, Maurizio, additional, d’Amati, Giulia, additional, Pignataro, Maria G, additional, Severino, Anna, additional, Cangemi, Roberto, additional, Arrivi, Alessio, additional, Dominici, Marcello, additional, Mangieri, Enrico, additional, Gaudio, Carlo, additional, Tanzilli, Gaetano, additional, and Violi, Francesco, additional

Published
2020
Full Text
View/download PDF

35. Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial

Author

Takahashi, Kuniaki, primary, Kogame, Norihiro, additional, Tomaniak, Mariusz, additional, Chichareon, Ply, additional, Chang, Chun-Chin, additional, Modolo, Rodrigo, additional, Benit, Edouard, additional, Liebetrau, Christoph, additional, Janssens, Luc, additional, Ferrario, Maurizio, additional, Zurakowski, Aleksander, additional, van Geuns, Robert Jan, additional, Dominici, Marcello, additional, Huber, Kurt, additional, Buszman, Pawel, additional, Bolognese, Leonardo, additional, Tumscitz, Carlo, additional, Żmudka, Krzysztof, additional, Aminian, Adel, additional, Vrolix, Mathias, additional, Petrov, Ivo, additional, Wykrzykowska, Joanna J., additional, de Winter, Robbert J., additional, Hamm, Christian, additional, Steg, Philippe Gabriel, additional, Onuma, Yoshinobu, additional, Valgimigli, Marco, additional, Windecker, Stephan, additional, Vranckx, Pascal, additional, Garg, Scot, additional, and Serruys, Patrick W., additional

Published
2019
Full Text
View/download PDF

36. [Updated SICI-GISE position paper on institutional and operator requirements for transcatheter aortic valve implantation]

Author

Tarantini, Giuseppe, Esposito, Giovanni, Musumeci, Giuseppe, Fraccaro, Chiara, Franzone, Anna, Castiglioni, Battistina, La Manna, Alessio, Limbruno, Ugo, Marchese, Alfredo, Mauro, Ciro, Rigattieri, Stefano, Tarantino, Fabio, Gandolfo, Caterina, Santoro, Gennaro, Violini, Roberto, Airoldi, Flavio, Albiero, Remo, Balbi, Manrico, Baralis, Giorgio, Bartorelli, Antonio Luca, Bedogni, Francesco, Benassi, Alberto, Berni, Andrea, Bonzani, Giulio, Bortone, Alessandro Santo, Braito, Giuseppe, Briguori, Carlo, Brscic, Elvis, Calabrò, Paolo, Calchera, Ivan, Cappelli Bigazzi, Maurizio, Caprioglio, Francesco, Castriota, Fausto, Cernetti, Carlo, Cicala, Cinzia, Cioffi, Paolo, Colombo, Antonio, Colombo, Virgilio, Contegiacomo, Gaetano, Cremonesi, Alberto, D'Amico, Maurizio, De Benedictis, Mauro, De Leo, Alessandro, Di Biasi, Maurizio, Di Girolamo, Domenico, Di Lorenzo, Emilio, Di Mario, Carlo, Dominici, Marcello, Ettori, Federica, Ferrario, Maurizio, Fioranelli, Massimo, Fischetti, Dionigi, Gabrielli, Gabriele, Giordano, Arturo, Giudice, Pietro, Greco, Cesare, Indolfi, Ciro, Leonzi, Ornella, Lettieri, Corrado, Loi, Bruno, Maddestra, Nicola, Marchionni, Niccolò, Marrozzini, Cinzia, Medda, Massimo, Missiroli, Bindo, My, Luigi, Oreglia, Jacopo Andrea, Palmieri, Cataldo, Pantaleo, Paolo, Paparoni, Saro Roberto, Parodi, Guido, Petronio, Anna Sonia, Piatti, Luigi, Piccaluga, Emanuela, Pierli, Carlo, Perkan, Andrea, Pitì, Antonino, Poli, Arnaldo, Ramondo, Angelo Bruno, Reale, Maurizio Alessandro, Reimers, Bernhard, Ribichini, Flavio Luciano, Rosso, Roberta, Saccà, Salvatore, Sacra, Cosimo, Santarelli, Andrea, Sardella, Gennaro, Satullo, Gaetano, Scalise, Filippo, Siviglia, Massimo, Spedicato, Leonardo, Stabile, Amerigo, Tamburino, Corrado, Tesorio, Tullio Nicola Maria, Tolaro, Salvatore, Tomai, Fabrizio, Trani, Carlo, Valenti, Renato, Valsecchi, Orazio, Valva, Giuseppe, Varbella, Ferdinando, Vigna, Carlo, Vignali, Luigi, Berti, Sergio, Tarantini, Giuseppe, Esposito, Giovanni, Musumeci, Giuseppe, Fraccaro, Chiara, Franzone, Anna, Castiglioni, Battistina, La Manna, Alessio, Limbruno, Ugo, Marchese, Alfredo, Mauro, Ciro, Rigattieri, Stefano, Tarantino, Fabio, Gandolfo, Caterina, Santoro, Gennaro, Violini, Roberto, Airoldi, Flavio, Albiero, Remo, Balbi, Manrico, Baralis, Giorgio, Bartorelli, Antonio Luca, Bedogni, Francesco, Benassi, Alberto, Berni, Andrea, Bonzani, Giulio, Bortone, Alessandro Santo, Braito, Giuseppe, Briguori, Carlo, Brscic, Elvi, Calabrò, Paolo, Calchera, Ivan, Cappelli Bigazzi, Maurizio, Caprioglio, Francesco, Castriota, Fausto, Cernetti, Carlo, Cicala, Cinzia, Cioffi, Paolo, Colombo, Antonio, Colombo, Virgilio, Contegiacomo, Gaetano, Cremonesi, Alberto, D'Amico, Maurizio, De Benedictis, Mauro, De Leo, Alessandro, Di Biasi, Maurizio, Di Girolamo, Domenico, Di Lorenzo, Emilio, Di Mario, Carlo, Dominici, Marcello, Ettori, Federica, Ferrario, Maurizio, Fioranelli, Massimo, Fischetti, Dionigi, Gabrielli, Gabriele, Giordano, Arturo, Giudice, Pietro, Greco, Cesare, Indolfi, Ciro, Leonzi, Ornella, Lettieri, Corrado, Loi, Bruno, Maddestra, Nicola, Marchionni, Niccolò, Marrozzini, Cinzia, Medda, Massimo, Missiroli, Bindo, My, Luigi, Oreglia, Jacopo Andrea, Palmieri, Cataldo, Pantaleo, Paolo, Paparoni, Saro Roberto, Parodi, Guido, Petronio, Anna Sonia, Piatti, Luigi, Piccaluga, Emanuela, Pierli, Carlo, Perkan, Andrea, Pitì, Antonino, Poli, Arnaldo, Ramondo, Angelo Bruno, Reale, Maurizio Alessandro, Reimers, Bernhard, Ribichini, Flavio Luciano, Rosso, Roberta, Saccà, Salvatore, Sacra, Cosimo, Santarelli, Andrea, Sardella, Gennaro, Satullo, Gaetano, Scalise, Filippo, Siviglia, Massimo, Spedicato, Leonardo, Stabile, Amerigo, Tamburino, Corrado, Tesorio, Tullio Nicola Maria, Tolaro, Salvatore, Tomai, Fabrizio, Trani, Carlo, Valenti, Renato, Valsecchi, Orazio, Valva, Giuseppe, Varbella, Ferdinando, Vigna, Carlo, Vignali, Luigi, and Berti, Sergio

Subjects
Transcatheter aortic valve implantation, Transcatheter aortic valve implantation, TAVI, severe aortic stenosis, Operators, Biomedical Technology, Requirements, Aortic Valve Stenosis, Institutions, Severity of Illness Index, Transcatheter Aortic Valve Replacement, TAVI, Italy, Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, Training, Humans, Program Development, severe aortic stenosis
Abstract

Transcatheter aortic valve implantation (TAVI) has revolutionized the management of patients with symptomatic severe aortic stenosis and has become the standard of care for inoperable patients and the preferred therapy for those at increased surgical risk with peculiar clinical and anatomic features. Technology advances, growing experience and accumulating data prompted the update of the 2011 Italian Society of Interventional Cardiology (SICI-GISE) position paper on institutional and operator requirements to perform TAVI. The main objective of this document is to provide a guidance to assess the potential of institutions and operators to initiate and maintain an efficient TAVI program.

Published
2018

37. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

Author

Vranckx, Pascal, Valgimigli, Marco, Jüni, Peter, Hamm, Christian, Steg, Philippe Gabriel, Heg, Dik, Van Es, Gerrit Anne, McFadden, Eugene P, Onuma, Yoshinobu, Van Meijeren, Cokky, Chichareon, Ply, Benit, Edouard, Möllmann, Helge, Janssens, Luc, Ferrario, Maurizio, Moschovitis, Aris, Zurakowski, Aleksander, Dominici, Marcello, Van Geuns, Robert Jan, Huber, Kurt, Slagboom, Ton, Serruys, Patrick W, Windecker, Stephan, and Investigators, GLOBAL LEADERS

Subjects
610 Medicine & health, 360 Social problems & social services
Abstract

BACKGROUND We hypothesised that ticagrelor, in combination with aspirin for 1 month, followed by ticagrelor alone, improves outcomes after percutaneous coronary intervention compared with standard antiplatelet regimens. METHODS GLOBAL LEADERS was a randomised, open-label superiority trial at 130 sites in 18 countries. Patients undergoing percutaneous coronary intervention with a biolimus A9-eluting stent for stable coronary artery disease or acute coronary syndromes were randomly assigned (1:1) to 75-100 mg aspirin daily plus 90 mg ticagrelor twice daily for 1 month, followed by 23 months of ticagrelor monotherapy, or standard dual antiplatelet therapy with 75-100 mg aspirin daily plus either 75 mg clopidogrel daily (for patients with stable coronary artery disease) or 90 mg ticagrelor twice daily (for patients with acute coronary syndromes) for 12 months, followed by aspirin monotherapy for 12 months. Randomisation was concealed, stratified by centre and clinical presentation (stable coronary artery disease vs acute coronary syndrome), and blocked, with randomly varied block sizes of two and four. The primary endpoint at 2 years was a composite of all-cause mortality or non-fatal centrally adjudicated new Q-wave myocardial infarction as assessed by a core lab in a blinded manner. The key secondary safety endpoint was site-reported bleeding assessed according to the Bleeding Academic Research Consortium criteria (grade 3 or 5). Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01813435, and is closed to new participants, with follow-up completed. FINDINGS Between July 1, 2013, and Nov 9, 2015, 15 968 participants were randomly assigned, 7980 to the experimental group and 7988 to the control group. At 2 years, 304 (3·81%) participants in the experimental group had died or had a non-fatal centrally adjudicated new Q-wave myocardial infarction, compared with 349 (4·37%) participants in the control group (rate ratio 0·87 [95% CI 0·75-1·01]; p=0·073]). There was no evidence for a difference in treatment effects for the primary endpoint across prespecified subgroups of acute coronary syndromes and stable coronary artery disease (p=0·93). Grade 3 or 5 bleeding occurred in 163 participants in the experimental group and 169 in the control group (2·04% vs 2·12%; rate ratio 0·97 [95% CI 0·78-1·20]; p=0·77). INTERPRETATION Ticagrelor in combination with aspirin for 1 month followed by ticagrelor alone for 23 months was not superior to 12 months of standard dual antiplatelet therapy followed by 12 months of aspirin alone in the prevention of all-cause mortality or new Q-wave myocardial infarction 2 years after percutaneous coronary intervention. FUNDING AstraZeneca, Biosensors, and The Medicines Company.

Published
2018
Full Text
View/download PDF

38. TCT-642 PARIS Risk Score Stratified Analysis of Clinical Outcomes Among Elderly Patients (Aged > 75 Years) Treated With 23-Month Ticagrelor Monotherapy Following 1-Month DAPT After PCI in the GLOBAL LEADERS Trial

Author

Tomaniak, Mariusz, primary, Chichareon, Ply, additional, Modolo, Rodrigo, additional, Takahashi, Kuniaki, additional, Kogame, Norihiro, additional, Chang, Chun-Chin, additional, Spitzer, Ernest, additional, Van Geuns, Robert-Jan, additional, Geisler, Tobias, additional, Prokopczuk, Janusz, additional, Sabate, Manel, additional, Rademaker-Havinga, Tessa, additional, Hamm, Christian, additional, Onuma, Yoshinobu, additional, Vranckx, Pascal, additional, Valgimigli, Marco, additional, Windecker, Stephan, additional, Baber, Usman, additional, Anderson, Richard, additional, Dominici, Marcello, additional, and Serruys, Patrick, additional

Published
2019
Full Text
View/download PDF

39. Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial

Author

Serruys, Patrick W, primary, Takahashi, Kuniaki, additional, Chichareon, Ply, additional, Kogame, Norihiro, additional, Tomaniak, Mariusz, additional, Modolo, Rodrigo, additional, Chang, Chun Chin, additional, Komiyama, Hidenori, additional, Soliman, Osama, additional, Wykrzykowska, Joanna J, additional, de Winter, Robbert J, additional, Ferrario, Maurizio, additional, Dominici, Marcello, additional, Buszman, Paweł, additional, Bolognese, Leonardo, additional, Tumscitz, Carlo, additional, Benit, Edouard, additional, Stoll, Hans-Peter, additional, Hamm, Christian, additional, Steg, Philippe Gabriel, additional, Onuma, Yoshinobu, additional, Jüni, Peter, additional, Windecker, Stephan, additional, Vranckx, Pascal, additional, Colombo, Antonio, additional, and Valgimigli, Marco, additional

Published
2019
Full Text
View/download PDF

40. Glutathione infusion before primary percutaneous coronary intervention: a randomised controlled pilot study

Author

Tanzilli, Gaetano, primary, Truscelli, Giovanni, additional, Arrivi, Alessio, additional, Carnevale, Roberto, additional, Placanica, Attilio, additional, Viceconte, Nicola, additional, Raparelli, Valeria, additional, Mele, Rita, additional, Cammisotto, Vittoria, additional, Nocella, Cristina, additional, Barillà, Francesco, additional, Lucisano, Luigi, additional, Pennacchi, Mauro, additional, Granatelli, Antonino, additional, Dominici, Marcello, additional, Basili, Stefania, additional, Gaudio, Carlo, additional, and Mangieri, Enrico, additional

Published
2019
Full Text
View/download PDF

41. LONG-TERM TICAGRELOR MONOTHERAPY IN ELDERLY PATIENTS UNDERGOING PCI IN THE GLOBAL LEADERS STUDY

Author

Tomaniak, Mariusz, primary, Chichareon, Ply, additional, Modolo, Rodrigo, additional, Takahashi, Kuniaki, additional, Chang, Chun Chin, additional, Kogame, Norihiro, additional, Katagiri, Yuki, additional, Cano, Ernest Spitzer, additional, Buszman, Pawel, additional, van Geuns, Robert, additional, Valkov, Veselin, additional, Geisler, Tobias, additional, Prokopczuk, Janusz, additional, Hamm, Christian, additional, Steg, Philippe, additional, Sabate, Manel, additional, Zmudka, Krzysztof, additional, Juni, Peter, additional, Onuma, Yoshinobu, additional, Vranckx, Pascal, additional, Valgimigli, Marco, additional, Windecker, Stephan, additional, Serruys, Patrick, additional, Anderson, Richard, additional, and Dominici, Marcello, additional

Published
2019
Full Text
View/download PDF

42. Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)

Author

Leonardi, Sergio, primary, Franzone, Anna, additional, Piccolo, Raffaele, additional, McFadden, Eugene, additional, Vranckx, Pascal, additional, Serruys, Patrick, additional, Benit, Edouard, additional, Liebetrau, Christoph, additional, Janssens, Luc, additional, Ferrario, Maurizio, additional, Zurakowski, Aleksander, additional, van Geuns, Robert-Jan, additional, Dominici, Marcello, additional, Huber, Kurt, additional, Slagboom, Ton, additional, Buszman, Paweł, additional, Bolognese, Leonardo, additional, Tumscitz, Carlo, additional, Bryniarski, Krzysztof, additional, Aminian, Adel, additional, Vrolix, Mathias, additional, Petrov, Ivo, additional, Garg, Scot, additional, Naber, Christoph, additional, Prokopczuk, Janusz, additional, Hamm, Christian, additional, Steg, Gabriel, additional, Heg, Dik, additional, Juni, Peter, additional, Windecker, Stephan, additional, and Valgimigli, Marco, additional

Published
2019
Full Text
View/download PDF

43. PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY

Author

Gragnano, Felice, Heg, Dik, Franzone, Anna, McFadden, Eugène P, Leonardi, Sergio, Piccolo, Raffaele, Vranckx, Pascal, Branca, Mattia, Serruys, Patrick W, Benit, Edouard, Liebetrau, Christoph, Janssens, Luc, Ferrario, Maurizio, Zurakowski, Aleksander, Diletti, Roberto, Dominici, Marcello, Huber, Kurt, Slagboom, Ton, Buszman, Paweł, Bolognese, Leonardo, Tumscitz, Carlo, Bryniarski, Krzysztof, Aminian, Adel, Vrolix, Mathias, Petrov, Ivo, Garg, Scot, Naber, Christoph, Prokopczuk, Janusz, Hamm, Christian, Steg, Philippe Gabriel, Jüni, Peter, Windecker, Stephan, and Valgimigli, Marco

Published
2022
Full Text
View/download PDF

44. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

Author

Vranckx, Pascal, primary, Valgimigli, Marco, additional, Jüni, Peter, additional, Hamm, Christian, additional, Steg, Philippe Gabriel, additional, Heg, Dik, additional, van Es, Gerrit Anne, additional, McFadden, Eugene P, additional, Onuma, Yoshinobu, additional, van Meijeren, Cokky, additional, Chichareon, Ply, additional, Benit, Edouard, additional, Möllmann, Helge, additional, Janssens, Luc, additional, Ferrario, Maurizio, additional, Moschovitis, Aris, additional, Zurakowski, Aleksander, additional, Dominici, Marcello, additional, Van Geuns, Robert Jan, additional, Huber, Kurt, additional, Slagboom, Ton, additional, Serruys, Patrick W, additional, Windecker, Stephan, additional, Abdellaoui, Mohamed, additional, Adlam, David, additional, Akin, Ibrahim, additional, Albarran Gonzalez-Trevilla, Agustin, additional, Almeida, Manuel, additional, Alves Lemos Neto, Pedro, additional, Aminian, Adel, additional, Anderson, Richard, additional, Andreae, Rick, additional, Angioi, Michael, additional, Asano, Taku, additional, Barbato, Emanuele, additional, Barlis, Peter, additional, Barraud, Pascal, additional, Bertrand, Olivier, additional, Beygui, Farzin, additional, Bolognese, Leonardo, additional, Botelho, Roberto, additional, Bouwman, Coby, additional, Bressers, Marco, additional, Brunel, Philippe, additional, Buszman, Pawel, additional, Buysschaert, Ian, additional, Canas da Silva, Pedro, additional, Carrie, Didier, additional, Cequier, Angel, additional, Chin Chang, Chun, additional, Chowdhary, Saqib, additional, Collet, Carlos, additional, Colombo, Antonio, additional, Cotton, James, additional, Cruz Ferreira, Rui, additional, Curello, Salvatore, additional, Curzen, Nick, additional, de Bot, Judith, additional, de Vreede, Tone, additional, Delle Karth, Georg, additional, Dijksma, Lynn, additional, Édes, István, additional, Eeckhout, Eric, additional, Eitel, Ingo, additional, Faluközy, József, additional, Fath-Ordoubadi, Farzin, additional, Fontos, Geza, additional, Francisco Diaz, Jose, additional, Freitas Quintella, Edgard, additional, Frey, Bernhard, additional, Friedrich, Guy, additional, Galasko, Gavin, additional, Galuszka, Grzegorz, additional, Gama Ribeiro, Vasco, additional, Garg, Scot, additional, Gargiulo, Giuseppe, additional, Geisler, Tobias, additional, Gelev, Valeri, additional, Ghandilyan, Art, additional, Goicolea, Javier, additional, Gori, Tommaso, additional, Gragnano, Felice, additional, Guimarães, Ana, additional, Haude, Michael, additional, Heijke, Pieter, additional, Hernández Antolin, Rosa Ana, additional, Hildick-Smith, David, additional, Hillen, Dorien, additional, Hoekman, Ina, additional, Hofma, Sjoerd, additional, Holmvang, Lene, additional, Hoole, Stephen, additional, Horváth, Iván, additional, Hugense, Annemarie, additional, Ibrahim, Karim, additional, Iñiguez, Andres, additional, Isaaz, Karl, additional, Jambrik, Zoltán, additional, Jasionowicz, Pawel, additional, Jonk, Judith, additional, Jung, Werner, additional, Katagiri, Yuki, additional, Kogame, Norihiro, additional, Koh, Tian Hai, additional, Koning, René, additional, Konteva, Mariana, additional, Kőszegi, Zsolt, additional, Krackhardt, Florian, additional, Kreuger, Yvonne, additional, Kukreja, Neville, additional, Ladan, Boudijn, additional, Lantelme, Pierre, additional, Leandro, Sergio, additional, Leibundgut, Gregor, additional, Liebetrau, Christoph, additional, Lindeboom, Wietze, additional, Macaya Miguel, Carlos, additional, Mach, François, additional, Magro, Michael, additional, Maillard, Luc, additional, Manavifar, Negar, additional, Mauri, Laura, additional, McFadden, Eugene, additional, Merkely, Bela, additional, Miyazaki, Yosuke, additional, Młodziankowski, Adam, additional, Moccetti, Tiziano, additional, Modolo, Rodrigo, additional, Möllman, Helge, additional, Morelle, Jean-François, additional, Munndt Ottesen, Michael, additional, Muurling, Martin, additional, Naber, Christoph Kurt, additional, Neumann, Franz-Josef, additional, Oldroyd, Keith, additional, Ong, Paul, additional, Palsrok, Sanne, additional, Petrov, Ivo, additional, Plante, Sylvain, additional, Prokopczuk, Janusz, additional, Rademaker-Havinga, Tessa, additional, Raffel, Christopher, additional, Rensing, Benno, additional, Roffi, Marco, additional, Royaards, Kees-Jan, additional, Sabate, Manel, additional, Schächinger, Volker, additional, Seidler, Tim, additional, Serra Peñaranda, Antonio, additional, Serruys, Patrick, additional, Sikarulidze, Lali, additional, Soliman, Osama I, additional, Sousa, Amanda, additional, Spitzer, Ernest, additional, Stables, Rod, additional, Steg, Gabriel, additional, Steinwender, Clemens, additional, Subkovas, Eduardas, additional, Suryapranata, Harry, additional, Takahashi, Kuniaki, additional, Talwar, Suneel, additional, Teiger, Emmanuel, additional, ter Weele, Addy, additional, Teurlings, Eva, additional, Thury, Attila, additional, Tijssen, Jan, additional, Tonev, Gincho, additional, Trendafilova-Lazarova, Diana, additional, Tumscitz, Carlo, additional, Umans, Victor, additional, Ungi, Imre, additional, Valkov, Veselin, additional, van der Harst, Pim, additional, van Geuns, Robert Jan, additional, Vassilev, Dobrin, additional, Velchev, Vasil, additional, Velthuizen, Esther, additional, Verheugt, Freek, additional, Vlcek, Natalia, additional, vom Dahl, Jürgen, additional, Vrolix, Mathias, additional, Walsh, Simon, additional, Werner, Nikos, additional, Witsenburg, Maarten, additional, Zaman, Azfar, additional, Żmudka, Krzysztof, additional, Zrenner, Bernhard, additional, and Zweiker, Robert, additional

Published
2018
Full Text
View/download PDF

45. TCT-170 Impact of rate of recruitment on all-cause mortality: Insights from the GLOBAL LEADERS all-comers trial

Author

Takahashi, Kuniaki, primary, Chichareon, Ply, additional, Dominici, Marcello, additional, Benit, Edouard, additional, Valkov, Veselin, additional, Liebetrau, Christoph, additional, Janssens, Luc, additional, Ferrario, Maurizio, additional, Aminian, Adel, additional, Sabate, Manel, additional, Kogame, Norihiro, additional, Modolo, Rodrigo, additional, Chang, Chun-Chin, additional, Onuma, Yoshinobu, additional, Valgimigli, Marco, additional, Windecker, Stephan, additional, Vranckx, Pascal, additional, and Serruys, Patrick, additional

Published
2018
Full Text
View/download PDF

47. Abstract 153: Gut Microbiota-derived Lipolysaccarides Are Enhnaced in the Coronary Thrombi of Patients With Myocardial Infarction

Author

Nocella, Cristina, primary, Carnevale, Roberto, additional, Calvieri, Camilla, additional, Cangemi, Roberto, additional, Cammisotto, Vittoria, additional, Mangeri, Enrico, additional, Dominici, Marcello, additional, Arrivi, Alessio, additional, Frati, Giacomo, additional, D'Amati, Giulia, additional, Tanzilli, Gaetano, additional, and Violi, Francesco, additional

Published
2018
Full Text
View/download PDF

48. Diagnostic Accuracy of Coronary CT Angiography for the Evaluation of Bioresorbable Vascular Scaffolds

Author

Collet, Carlos, primary, Chevalier, Bernard, additional, Cequier, Angel, additional, Fajadet, Jean, additional, Dominici, Marcello, additional, Helqvist, Steffen, additional, Van Boven, Ad J., additional, Dudek, Dariusz, additional, McClean, Dougal, additional, Almeida, Manuel, additional, Piek, Jan J., additional, Tenekecioglu, Erhan, additional, Bartorelli, Antonio, additional, Windecker, Stephan, additional, Serruys, Patrick W., additional, and Onuma, Yoshinobu, additional

Published
2018
Full Text
View/download PDF

49. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vsaspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

Author

Vranckx, Pascal, Valgimigli, Marco, Jüni, Peter, Hamm, Christian, Steg, Philippe Gabriel, Heg, Dik, van Es, Gerrit Anne, McFadden, Eugene P, Onuma, Yoshinobu, van Meijeren, Cokky, Chichareon, Ply, Benit, Edouard, Möllmann, Helge, Janssens, Luc, Ferrario, Maurizio, Moschovitis, Aris, Zurakowski, Aleksander, Dominici, Marcello, Van Geuns, Robert Jan, Huber, Kurt, Slagboom, Ton, Serruys, Patrick W, Windecker, Stephan, Abdellaoui, Mohamed, Adlam, David, Akin, Ibrahim, Albarran Gonzalez-Trevilla, Agustin, Almeida, Manuel, Alves Lemos Neto, Pedro, Aminian, Adel, Anderson, Richard, Andreae, Rick, Angioi, Michael, Asano, Taku, Barbato, Emanuele, Barlis, Peter, Barraud, Pascal, Benit, Edouard, Bertrand, Olivier, Beygui, Farzin, Bolognese, Leonardo, Botelho, Roberto, Bouwman, Coby, Bressers, Marco, Brunel, Philippe, Buszman, Pawel, Buysschaert, Ian, Canas da Silva, Pedro, Carrie, Didier, Cequier, Angel, Chichareon, Ply, Chin Chang, Chun, Chowdhary, Saqib, Collet, Carlos, Colombo, Antonio, Cotton, James, Cruz Ferreira, Rui, Curello, Salvatore, Curzen, Nick, de Bot, Judith, de Vreede, Tone, Delle Karth, Georg, Dijksma, Lynn, Dominici, Marcello, Édes, István, Eeckhout, Eric, Eitel, Ingo, Faluközy, József, Fath-Ordoubadi, Farzin, Ferrario, Maurizio, Fontos, Geza, Francisco Diaz, Jose, Freitas Quintella, Edgard, Frey, Bernhard, Friedrich, Guy, Galasko, Gavin, Galuszka, Grzegorz, Gama Ribeiro, Vasco, Garg, Scot, Gargiulo, Giuseppe, Geisler, Tobias, Gelev, Valeri, Ghandilyan, Art, Goicolea, Javier, Gori, Tommaso, Gragnano, Felice, Guimarães, Ana, Hamm, Christian, Haude, Michael, Heg, Dik, Heijke, Pieter, Hernández Antolin, Rosa Ana, Hildick-Smith, David, Hillen, Dorien, Hoekman, Ina, Hofma, Sjoerd, Holmvang, Lene, Hoole, Stephen, Horváth, Iván, Huber, Kurt, Hugense, Annemarie, Ibrahim, Karim, Iñiguez, Andres, Isaaz, Karl, Jambrik, Zoltán, Janssens, Luc, Jasionowicz, Pawel, Jonk, Judith, Jung, Werner, Jüni, Peter, Katagiri, Yuki, Kogame, Norihiro, Koh, Tian Hai, Koning, René, Konteva, Mariana, Kőszegi, Zsolt, Krackhardt, Florian, Kreuger, Yvonne, Kukreja, Neville, Ladan, Boudijn, Lantelme, Pierre, Leandro, Sergio, Leibundgut, Gregor, Liebetrau, Christoph, Lindeboom, Wietze, Macaya Miguel, Carlos, Mach, François, Magro, Michael, Maillard, Luc, Manavifar, Negar, Mauri, Laura, McFadden, Eugene, Merkely, Bela, Miyazaki, Yosuke, Młodziankowski, Adam, Moccetti, Tiziano, Modolo, Rodrigo, Möllman, Helge, Morelle, Jean-François, Moschovitis, Aris, Munndt Ottesen, Michael, Muurling, Martin, Naber, Christoph Kurt, Neumann, Franz-Josef, Oldroyd, Keith, Ong, Paul, Onuma, Yoshinobu, Palsrok, Sanne, Petrov, Ivo, Plante, Sylvain, Prokopczuk, Janusz, Rademaker-Havinga, Tessa, Raffel, Christopher, Rensing, Benno, Roffi, Marco, Royaards, Kees-Jan, Sabate, Manel, Schächinger, Volker, Seidler, Tim, Serra Peñaranda, Antonio, Serruys, Patrick, Sikarulidze, Lali, Slagboom, Ton, Soliman, Osama I, Sousa, Amanda, Spitzer, Ernest, Stables, Rod, Steg, Gabriel, Steinwender, Clemens, Subkovas, Eduardas, Suryapranata, Harry, Takahashi, Kuniaki, Talwar, Suneel, Teiger, Emmanuel, ter Weele, Addy, Teurlings, Eva, Thury, Attila, Tijssen, Jan, Tonev, Gincho, Trendafilova-Lazarova, Diana, Tumscitz, Carlo, Umans, Victor, Ungi, Imre, Valkov, Veselin, van der Harst, Pim, van Geuns, Robert Jan, van Meijeren, Cokky, Vassilev, Dobrin, Velchev, Vasil, Velthuizen, Esther, Verheugt, Freek, Vlcek, Natalia, vom Dahl, Jürgen, Vrolix, Mathias, Walsh, Simon, Werner, Nikos, Windecker, Stephan, Witsenburg, Maarten, Zaman, Azfar, Żmudka, Krzysztof, Zrenner, Bernhard, Zurakowski, Aleksander, and Zweiker, Robert

Abstract

We hypothesised that ticagrelor, in combination with aspirin for 1 month, followed by ticagrelor alone, improves outcomes after percutaneous coronary intervention compared with standard antiplatelet regimens.

Published
2018
Full Text
View/download PDF

50. A Giant Coronary Artery Aneurysm with Coronary Arteriovenous Fistula in Asymptomatic Elderly Patient

Author

Milici, Caterina, Bovelli, Daniella, Borghetti, Valentino, Khoury, Georgette, Bazzucchi, Marco, Principi, Massimo, Dominici, Marcello, and Boschetti, Enrico

Subjects
Article Subject
Abstract

Coronary Arteriovenous Fistula (CAF) is a rare defect that occurs in 0.1-0.2% of patients undergoing coronary angiography; Coronary Artery Aneurism (CAA) also occurs in approximately 15–19% of patients with CAF. It is usually congenital, but in rare occasions it occurs after chest trauma, cardiac surgery, or coronary interventions. The case described is that of a 72-year-old woman, without previous history of cardiovascular disease, who presented a huge cardiac mass. A multimodal approach was necessary to diagnose a giant CAA with CAF responsible for compression and displacement of cardiac structures. Due to likely congenitally origin of the lesion and the absence of symptoms correlated to the CAA and to the CAF we decided to avoid invasive interventions and to treat the patient with medical therapy.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results